ERT’s Scientific and Regulatory Consultants Support Phase III Oncology Trial
Provectus Biopharmaceuticals Collaborates with ERT’s COA Experts to Understand Patient Perspective during Melanoma Drug Development.
Provectus Biopharmaceuticals Collaborates with ERT’s COA Experts to Understand Patient Perspective during Melanoma Drug Development.
ERT’s Solutions Utilized in over Half of FDA Approvals.
Sartorius, a leading international laboratory and pharmaceutical equipment provider, completed the sale of its Industrial Technologies Division to the Japanese Minebea Co., Ltd. and their partner, the Development Bank of Japan Inc., which had been agreed on December 19, 2014. The cash proceeds resulting from this transaction total approximately €90 million.
Sartorius have signed an agreement with the Japanese Minebea Group about the sale of our Industrial Technologies Division (Intec). The sales transaction is expected to be completed already in the first quarter of 2015. Based on our intensive negotiations with the future owner, we are convinced that Minebea will offer an excellent new roof for our Intec activities to enable the further dynamic development and internationalisation of this business. Given the portfolios and the regional presence of both companies, there is a strong complementary fit and thus significant synergy potential for the further profitable growth of this activity.
3R Pharma managing director Manuel Zahn will lead workshops, conferences and seminars this March.
Woodley Equipment Company is exhibiting at Outsourcing in Clinical Trials West Coast taking place at the Hyatt Regency San Francisco Airport Hotel on 3 – 4 February 2015.
A completely new gel permeation/size exclusion chromatography (GPC/SEC) platform from Malvern Instruments breaks new ground in delivering the high performance, ease of use and productivity demanded in today’s analytical laboratories. Malvern’s innovative OMNISEC platform integrates highly efficient sample separation via the OMNISEC RESOLVE module and high sensitivity analysis using OMNISEC REVEAL, a fully integrated multi-detector array. The system has applications wherever there is a need for detailed analysis and understanding of natural or synthetic polymers, proteins and macromolecules.
• Group sales revenue +12.6%, order intake +13.4%, underlying EBITDA +15.1%
• Dynamic growth in the Bioprocess Solutions Division; positive trend for the
Lab Products & Services Division
• Sartorius expects significant increases in sales and earnings for 2015 as well.
Fixed dose combinations are desirable for several reasons such as different release profiles and guaranteeing patients´ compliance by reducing the daily intake of a drug product(s).
The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and single-use vessel flexibility, intelligent sensors, and IP network communication for multi-unit control set it apart as the new premium choice in the bench scale bioprocess market.